Intercept Pharmaceuticals (NASDAQ:ICPT) Lifted to Hold at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from a sell rating to a hold rating in a report released on Thursday, BidAskClub reports.

A number of other equities analysts also recently issued reports on the company. Royal Bank of Canada set a $135.00 price objective on Intercept Pharmaceuticals and gave the stock a buy rating in a research report on Friday, September 6th. ValuEngine upgraded Intercept Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, August 1st. Wedbush set a $243.00 price objective on Intercept Pharmaceuticals and gave the stock a buy rating in a research report on Friday, July 5th. Citigroup upgraded Intercept Pharmaceuticals from a neutral rating to a buy rating and lowered their price objective for the stock from $106.00 to $85.00 in a research report on Wednesday, September 4th. Finally, Zacks Investment Research raised Intercept Pharmaceuticals from a sell rating to a hold rating and set a $73.00 target price for the company in a research note on Monday, July 15th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have given a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $133.40.

Shares of ICPT opened at $68.90 on Thursday. Intercept Pharmaceuticals has a 1 year low of $58.21 and a 1 year high of $133.74. The company has a debt-to-equity ratio of 3.11, a quick ratio of 6.54 and a current ratio of 6.54. The business has a 50-day moving average of $63.96 and a 200-day moving average of $84.05.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($2.28) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($2.51) by $0.23. Intercept Pharmaceuticals had a negative return on equity of 534.42% and a negative net margin of 143.57%. The company had revenue of $66.30 million during the quarter, compared to the consensus estimate of $58.78 million. During the same period last year, the company earned ($2.58) earnings per share. The firm’s revenue was up 52.2% compared to the same quarter last year. Sell-side analysts predict that Intercept Pharmaceuticals will post -9.99 EPS for the current fiscal year.

In other Intercept Pharmaceuticals news, Director Srinivas Akkaraju purchased 5,207 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were acquired at an average cost of $60.32 per share, for a total transaction of $314,086.24. Following the completion of the acquisition, the director now owns 21,526 shares of the company’s stock, valued at approximately $1,298,448.32. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Lisa Bright sold 595 shares of Intercept Pharmaceuticals stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $78.66, for a total value of $46,802.70. Following the sale, the insider now owns 20,452 shares in the company, valued at $1,608,754.32. The disclosure for this sale can be found here. 5.00% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of ICPT. AdvisorNet Financial Inc bought a new stake in shares of Intercept Pharmaceuticals in the second quarter valued at $56,000. Botty Investors LLC bought a new stake in shares of Intercept Pharmaceuticals in the first quarter valued at $84,000. Compagnie Lombard Odier SCmA bought a new stake in shares of Intercept Pharmaceuticals in the second quarter valued at $80,000. NumerixS Investment Technologies Inc bought a new stake in shares of Intercept Pharmaceuticals in the second quarter valued at $88,000. Finally, Coastal Investment Advisors Inc. raised its stake in shares of Intercept Pharmaceuticals by 124.9% in the second quarter. Coastal Investment Advisors Inc. now owns 1,417 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 787 shares during the period. Institutional investors and hedge funds own 80.97% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Further Reading: How interest rates affect municipal bond prices

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Expedia Group  Receives Buy Rating from Barclays
Expedia Group Receives Buy Rating from Barclays
MRC Global Inc  Short Interest Update
MRC Global Inc Short Interest Update
Equitrans Midstream’s  “Hold” Rating Reiterated at Barclays
Equitrans Midstream’s “Hold” Rating Reiterated at Barclays
Huazhu Group’s  Sell Rating Reaffirmed at Daiwa Capital Markets
Huazhu Group’s Sell Rating Reaffirmed at Daiwa Capital Markets
BidaskClub Downgrades Changyou.Com  to Sell
BidaskClub Downgrades Changyou.Com to Sell
Cantor Fitzgerald Analysts Give UnitedHealth Group  a $310.00 Price Target
Cantor Fitzgerald Analysts Give UnitedHealth Group a $310.00 Price Target


© 2006-2019 Ticker Report